Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 15/20 | 1.00 |
| ▸ | NAALAD2 | Q9Y3Q0 | 4/20 | 0.78 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.75 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17241614 | 1.00 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLAMEN1ALDH1A1 | |
| SCHEMBL19611501 | 1.00 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLAMEN1ALDH1A1 | |
| SCHEMBL22883311 | 0.90 | FOLH1 (0.81) | FOLH1NAALAD2RIMKLAMEN1ALDH1A1 | |
| SCHEMBL22618719 | 0.87 | FOLH1 (0.78) | FOLH1NAALAD2RIMKLAMEN1ALDH1A1 | |
| SCHEMBL18161468 | 0.87 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL14102870 | 0.87 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL12145776 | 0.87 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL1377049 | 0.87 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL14102890 | 0.87 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL28214706 | 0.87 | ALDH1A1 (0.88) | FOLH1NAALAD2MEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911488-B2 | Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy | THE JOHNS HOPKINS UNIVERSTY (US) | 2024-02-27 | — | — | US | disclosed |
| US-20200360542-A1 | SCAFFOLDS AND MULTIFUNCTIONAL INTERMEDIATES FOR IMAGING PSMA AND CANCER THERAPY | THE JOHNS HOPKINS UNIVERSTY | 2020-11-19 | — | — | US | disclosed |
| US-10736974-B2 | Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-08-11 | — | — | US | disclosed |
| US-20170333576-A1 | NEW SCAFFOLDS AND MULTIFUNCTIONAL INTERMEDIATES FOR IMAGING PSMA AND CANCER THERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-11-23 | — | — | US | disclosed |
| WO-2012082903-A2 | TREATMENT OF COGNITIVE IMPAIRMENT IN A SUBJECT WITH A NEUROLOGICAL AUTOIMMUNE DISEASE | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200360542-A1 | SCAFFOLDS AND MULTIFUNCTIONAL INTERMEDIATES FOR IMAGING PSMA AND CANCER THERAPY | FOLH1, PSMA3, PSMA7 | FOLH1 1/4885NAALAD2 189/4885RIMKLA 155/4885 |
| US-11911488-B2 | Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy | FOLH1, PSMA3, PSMA7 | FOLH1 1/4885NAALAD2 189/4885RIMKLA 155/4885 |
| US-20170333576-A1 | NEW SCAFFOLDS AND MULTIFUNCTIONAL INTERMEDIATES FOR IMAGING PSMA AND CANCER THERAPY | FOLH1, PSMA3, PSMA7 | FOLH1 1/4885NAALAD2 163/4885RIMKLA 127/4885 |
| US-10736974-B2 | Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy | FOLH1, PSMA3, PSMA7 | FOLH1 1/4885NAALAD2 189/4885RIMKLA 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.